Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing GP2, an immunotherapy candidate for preventing breast cancer recurrence. The company has not yet generated revenue and is still in the research, clinical development, and financing phase, with operations centered on advancing its pipeline toward regulatory approval and eventual commercialization.

1.06

— Greenwich LifeSciences, Inc.
	%
Pipeline drug candidate	100% Development of GP2, a therapeutic candidate intended to reduce breast cancer recurrence.
Clinical development	0% Designing and running clinical trials needed to generate safety and efficacy data.
Regulatory and commercialization preparation	0% Activities to support future approval, manufacturing scale-up, and launch readiness.

The company does not yet have commercial customers because it has not generated revenue or launched a product...

Clinical trial ecosystemprimary
Hospitals, investigators, and trial participants involved in testing GP2 and generating clinical data.
Regulatory agenciesprimary
FDA and other regulators that review trial results and determine whether the product can be approved.
Future oncology prescribers and patientsemerging
Breast cancer specialists and patients who would use GP2 if it reaches commercialization.

The company is headquartered in the United States and its reported activity is centered there...

•Headquartered in the United States
•No revenue by geography disclosed because the company is pre-revenue
•Clinical development and corporate functions are primarily U.S.-based
•Future commercialization would likely begin in the U.S. market

The company’s strategy is to advance GP2 through clinical development, secure regulatory approval, and build the...

Clinical development of GP2short-term

Clinical data is the core value driver and determines whether the program can progress toward approval.

Capital raising and liquidity managementshort-term

The company has no revenue and must fund operations through external financing.

Commercial readinessmedium-term

If development succeeds, the company will need manufacturing, marketing, sales, and distribution capabilities.

Greenwich LifeSciences is exposed to the typical risks of a clinical-stage biotech company: trial failure, regulatory...

critical

Clinical development failure

If GP2 does not demonstrate sufficient safety or efficacy, the program may not advance to approval.

Scope: Pipeline value and future commercialization
Materiality: high

high

Financing and liquidity risk

The company has no revenue and expects to continue incurring losses, so it must raise capital to fund operations.

Scope: Cash balance, ATM offerings, debt/equity financing, related-party support
Materiality: high

high

Regulatory approval risk

Even positive clinical data may not translate into timely approval or favorable labeling.

Scope: Time to market and commercialization prospects
Materiality: high

medium

Operating loss expansion

Clinical and public-company costs are expected to rise as development progresses.

Scope: R&D, G&A, stock-based compensation
Materiality: medium

Going-concern assessment

Affects investor assessment of survival risk and financing needs

Stock-based compensation

Raises reported R&D and G&A expenses without cash outflow

Accrued expenses and clinical cost estimates

Can materially affect quarterly operating losses

Equity financing and related-party funding

Affects cash flow, dilution, and balance sheet presentation

Greenwich LifeSciences, Inc.

Clinical development failure

Financing and liquidity risk

Regulatory approval risk

Operating loss expansion

REVVITY, INC.

PharmaCyte Biotech, Inc.

CG Oncology, Inc.

DYADIC INTERNATIONAL INC

Zeo ScientifiX, Inc.

Regenerative Medical Technology Group Inc.